residual viable tumor
Recently Published Documents


TOTAL DOCUMENTS

10
(FIVE YEARS 4)

H-INDEX

4
(FIVE YEARS 1)

2021 ◽  
Author(s):  
Jinpeng Huang ◽  
Feiye Wang ◽  
Xiaohua Du ◽  
Yongfen Li ◽  
Yuanyuan Zhuang ◽  
...  

Abstract Background pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare subset of lung cancer with a poor prognosis. As LCNEC is an uncommon malignancy, the optimal treatment for LCNEC has not been established. Case presentation : we report a case of a 66-year-old man diagnosed with unresectable, locally advanced LCNEC who presented a partial radiographic response to immunotherapy combined with chemotherapy. Salvage surgery was performed after 4 cycles of docetaxel and cisplatin (DP) regimen plus sintilimab, which is a highly selective, fully human antiprogrammed death-ligand 1 monoclonal antibody. Moreover, a pathologic analysis of the resected piece revealed the absence of residual viable tumor cells. Conclusion this case suggests that patients with locally advanced LCNEC may benefit from neoadjuvant chemo-immunotherapy, it is worthy for further study.


2020 ◽  
Vol 4 (1) ◽  
Author(s):  
Yun Ling ◽  
Ning Li ◽  
Lin Li ◽  
Changyuan Guo ◽  
Jiacong Wei ◽  
...  

AbstractNeoadjuvant immunotherapy provides a unique opportunity for understanding therapeutic responses. We analyzed pathologic responses in surgical specimens obtained from 31 squamous non-small cell lung cancer (NSCLC) patients receiving neoadjuvant anti-PD-1 treatment. Fifteen (48.4%) patients achieved pathologic complete response (pCR) or major pathologic response (MPR). Among them, seven (46.7%) were assessed as radiological partial response and eight (53.3%) as stable disease. Among 20 patients with pathologically identified tumor beds in lymph nodes (LNs), 10 and six patients achieved pCR/MPR in primary tumors and paired LNs, respectively. pCR was achieved in 6/19 N1 nodes and 1/7 N2 nodes. Residual viable tumor (RVT) cells in 8/9 MPR specimens had 100% immune-activated phenotype, while a median of 80% of RVT cells in pathologic nonresponse specimens presented immune-excluded/desert phenotype. These findings demonstrated that assessment of pathologic responses in both primary tumor and LNs may be important as a surrogate for assessing neoadjuvant immunotherapeutic efficacy.


2019 ◽  
Vol 15 (2) ◽  
pp. 107-117
Author(s):  
A. P. Kazanstev ◽  
Kh. I. Jumaniyozov ◽  
P. A. Kerimov ◽  
M. V. Rubanskaya ◽  
M. A. Rubanskiy ◽  
...  

Background. Despite significount successes in treatment of rhabdomyosarcoma of urogenital system in children there are unresolved questions of choise of optimal chemotherapys combinations, intensity of chemotherapy, volumes and terms of radiotherapy, tactics of treatment residual tumors in last 3 decades.The objective: show 15 years experience of treatment local and locally prevalent rhabdomyosarcoma urogenital system in children. The prognosis for children and adolescents with rhabdomyosarcoma has improved with refinements in multi-modal therapy.Materials and methods. In reseach are included 86 patients with a median age of 8.4 (0.7–17) with a local genitourinary rhabdomyosarcoma, treated in N.N. Blokhin National Medical Research Centre of Oncology from 2000 to 2016. All patients were treated in different riskadopted clinical protocol included chemotherapy and radiotherapy (IRS, SIOP, CWS and local protocol DORMS-6).Results. A 10-year overall survival and disease-free survival rates were 76 and 72 % in the entire group rhabdomyosarcoma patients, respectively.Conclusion. The effectiveness of the risk-adopted strategy in the genitourinary rhabdomyosarcoma treatment as well as the need of new approaches and in the cases of residual viable tumor after induction chemotherapy was demonstrated. 


2019 ◽  
Vol 52 (1) ◽  
pp. 24-32 ◽  
Author(s):  
Juliana Romanato ◽  
Marcos Roberto Menezes ◽  
Allan de Oliveira Santos ◽  
Regis Otaviano Franca Bezerra ◽  
Mariana Cunha Lopes Lima ◽  
...  

Abstract Objective: To determine whether 18F-fluorodeoxyglucose positron emission tomography/computed tomography performed immediately after percutaneous ablation (iPA18F-FDG PET/CT) is useful in evaluating the outcomes of the procedure. Materials and Methods: This was a retrospective study of 20 patients (13 males, 7 females; mean age, 65.8 ± 12.1 years) submitted to percutaneous ablation of metastases. All of the lesions treated had shown focal uptake on a 18F-FDG PET/CT scan obtained at baseline. The primary tumors were mainly colorectal cancer (in 45%) or lung cancer (in 40%). iPA18F-FDG PET/CT was performed to identify any residual viable tumor cells. The treatment was considered a success (no viable tumor cells present) if no uptake of 18F-FDG was noted on the iPA18F-FDG PET/CT scan. Results: Twenty-six lesions were submitted to percutaneous ablation with either cryoablation (n = 7) or radiofrequency ablation (n = 19). The mean lesion diameter was 2.52 ± 1.49 cm. For the detection of viable tumor cells, iPA18F-FDG PET/CT had a sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of 66.7%, 95%, 88.5%, 80%, and 90.5%, respectively. There was a significant correlation between the iPA18F-FDG PET/CT findings and the results of the follow-up studies (kappa = 0.66; p < 0.01). Conclusion: iPA18F-FDG PET/CT studies appear to constitute a useful means of evaluating the outcomes of percutaneous ablation. By detecting residual viable tumor cells, this strategy might allow early re-intervention, thus reducing morbidity. Studies involving larger numbers of patients are needed in order to confirm our findings.


2017 ◽  
Vol 115 (6) ◽  
pp. 752-759 ◽  
Author(s):  
Seung Hyun Kim ◽  
Kyoo‐Ho Shin ◽  
Seong‐Hwan Moon ◽  
Youngho Kong ◽  
Jin‐Suck Suh ◽  
...  

2006 ◽  
Vol 9 (3) ◽  
pp. 229-233 ◽  
Author(s):  
Annikka Weissferdt ◽  
Kim Neuling ◽  
Martin English ◽  
Suren Arul ◽  
Dominic McMullan ◽  
...  

We report the case of an 11-year-old girl with a retroperitoneal tumor in the left upper quadrant. The girl was admitted to hospital with weight loss and a painless abdominal mass that on biopsy was diagnosed as a peripheral primitive neuroectodermal tumor/Ewing sarcoma (pPNET/EWS) of the soft tissue. The patient underwent chemotherapy followed by surgical resection of the tumor 5 months after diagnosis. The posttreatment residual viable tumor showed a morphologic appearance resembling a neuroblastoma. Interphase and metaphase fluorescent in situ hybridization (FISH) studies performed on the pretreatment and posttreatment samples showed the presence of a t(11;22) rearrangement resulting in EWSR1/FLI1 gene fusion consistent with pPNET/EWS in both specimens. This case is unusual in the sense of showing the typical gene fusion for pPNET/EWS both in the pretherapy sample with the typical morphological appearance of this tumor and in the posttherapy specimen showing neural differentiation suggestive of a neuroblastoma.


1987 ◽  
Vol 5 (7) ◽  
pp. 1064-1070 ◽  
Author(s):  
R Motzer ◽  
G Bosl ◽  
R Heelan ◽  
W Fair ◽  
W Whitmore ◽  
...  

Forty-one advanced seminoma patients with normal biochemical markers and a complete or partial radiographic response after cisplatin-based chemotherapy had a complete reevaluation of all known sites of disease. Twenty-three patients had a residual mass, and in 14 the mass was greater than or equal to 3 cm. Nineteen patients with a residual mass, including 13 with a mass greater than or equal to 3 cm in diameter, had surgical excision or biopsy. Four patients had viable seminoma and one patient had teratoma; all five of these patients had residual masses greater than or equal to 3 cm. Four patients with a residual mass were observed without surgery. One patient with a residual mass greater than or equal to 3 cm progressed with biopsy-proven seminoma. Therefore, six of 14 patients (42%) with a residual mass greater than or equal to 3 cm had viable residual tumor. Eighteen patients had no residual mass after chemotherapy. Ten of these patients had surgery or biopsy; none had viable tumor, but two have relapsed. Eight patients were observed and none have relapsed. Advanced seminoma patients with a residual mass greater than or equal to 3 cm after chemotherapy are at high risk for residual viable tumor. Additional therapy is indicated for these patients. For patients with normal imaging studies or a residual mass less than 3 cm, close observation without surgery is generally possible.


Sign in / Sign up

Export Citation Format

Share Document